Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors
"The Report Global
Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence
and Increased Uptake of Immune Checkpoint Inhibitors provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About Oncology Market
In 2012, there were 32.6 million
people living with any type of cancer within five years of diagnosis.
These are generally incurable once they progress to the stage where
they are unresectable. Chemotherapy compounds are a mainstay
treatment for cancers of all types, at various disease stages. In a
typical course of therapy for cancer, multiple chemotherapy compounds
are administered sequentially in combination regimens, as an adjunct
to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to
dividing cells, meaning that they act on both healthy and malignant
tissues and are fairly toxic. However, they exert more damage on
malignant tissue than healthy tissue due to the rapid cell cycle of
cancer cells. The key cancer indications of this report are breast,
colorectal, lung, and prostate and hematological cancers.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1245341
A number of common etiologic
factors have been strongly characterized as raising the risk of
developing cancer, including age, chronic inflammation, gender,
obesity, tobacco usage and heritable cancer syndromes. The risk of
cancer increases greatly in patients over the age of 65. Populations
in developed countries are projected to become increasingly aged and
show rising obesity incidence, which will drive both cancer
prevalence and revenue growth for its treatments.
There
has been a shift towards developing targeted therapies, such as mAbs
and cell therapies. Targeted therapies, by their nature, have less
toxicity associated with their use and as a result can be
administered to more cancer patients, who are commonly elderly and
have co-morbidities, therefore increasing the overall survival of
this group and the number of treatment cycles they may receive. The
most commercially successful oncology treatments are mAbs such as
MabThera/Rituxan, Avastin and Herceptin.
Scope
Global revenue for the
oncology market is forecast to grow at a Compound Annual Growth Rate
(CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in
2023. Which drugs will achieve blockbuster status and how will the
key player companies perform during the forecast period?
The oncology pipeline is large
and fairly diverse and contains 7,773 products. How does the
composition of the pipeline compare with that of the existing market?
What are the most popular types of molecule type and molecular target
in the pipeline?
What mechanisms of action and
molecule types are most common for pipeline products being trialed in
the various key indications?
How will the market shares and
CAGRs of the top 20 pharma companies compare within oncology?
What proportion of the key
players’ revenues will be attributable to oncology products?
View
Sample PDF @
https://www.marketresearchreports.biz/reports/1245341/global-oncology-to-robust-market-research-reports.pdf
Reasons to buy
Understand the current
clinical and commercial landscape by considering disease
pathogenesis, diagnosis, prognosis, and the treatment options
available at each stage of diagnosis
Visualize the composition of
the oncology market across each indication, in terms of dominant
molecule types and targets, highlighting the key commercial assets
and players
Analyze the oncology pipeline
and stratify by stage of development, molecule type and molecular
target, with a granular breakdown across key indications
Understand the growth in
patient epidemiology and market revenue for the oncology market
globally and across the key players and product types
Stratify the market in terms
of the generic and premium product revenue split between oncology
products and assess the role of these product types in the treatment
of the various cancers
Identify commercial
opportunities in the oncology deals landscape by analyzing trends in
licensing and co-development deals.
View Report @
Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 11
2.3 Diagnosis 12
2.4 Etiology and Pathophysiology
13
2.4.1 Etiology 13
2.4.2 Pathophysiology 15
2.5 Co-morbidities and
Complications 16
2.6 Epidemiology Patterns -
Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage
Rates 17
2.6.1 Breast Cancer 17
2.6.2 Colorectal Cancer 18
2.6.3 Lung Cancer 19
2.6.4 Prostate Cancer 20
2.6.5 Hematological Cancers 21
2.7 Prognosis 22
2.7.1 Breast Cancer 22
2.7.2 Colorectal Cancer 23
2.7.3 Non-Small-Cell Lung Cancer
23
2.7.4 Prostate Cancer 24
2.8 Treatment 25
2.8.1 Surgery and Radiation
Therapy 25
2.8.2 Chemotherapy 26
2.8.3 Hormonal Therapies 28
2.8.4 Targeted Therapies 29
3 Key Marketed Products 31
3.1 Overview 31
3.2 MabThera/Rituxan (rituximab)
32
3.3 Avastin (bevacizumab) 33
3.4 Herceptin (trastuzumab) 35
3.5 Revlimid (lenalidomide) 37
3.6 Opdivo (nivolumab) 39
3.7 Xtandi (enzalutamide) 41
3.8 Gleevec/Glivec (imatinib
mesylate) 42
3.9 Alimta (pemetrexed) 44
3.10 Zytiga (abiraterone acetate)
46
3.11 Conclusion 47
4 Pipeline Landscape Assessment 49
4.1 Overview 49
4.2 Pipeline Development Landscape
50
4.3 Molecular Targets in the
Pipeline 54
4.4 Clinical Trials 58
4.4.1 Failure Rate by Stage of
Development, Indication, Molecule Type and Molecular Target 58
4.4.2 Clinical Trial Size and
Duration by Stage of Development, Indication, Molecule Type and
Molecular Target 62
4.4.3 Clinical Trial Size and
Duration by Stage of Development, Indication, Molecule Type and
Molecular Target 66
4.4.4 Aggregate Clinical Program
Size by Stage of Development, Indication, Molecule Type and Molecular
Target 70
4.4.5 Conclusion 74
4.5 Assessment of Key Pipeline
Products 74
4.5.1 Durvalumab - AstraZeneca 74
4.5.2 Durvalumab and Tremelimumab
- AstraZeneca 75
4.5.3 Abemaciclib - Eli Lilly 76
4.5.4 Rova-T (rovalpituzumab
tesirine) - AbbVie 77
4.5.5 Neratinib - Puma
Biotechnology 79
4.5.6 Acalabrutinib - AstraZeneca
80
4.5.7 KTE-C19 (Axicabtagene
Ciloleucel) - Kite Pharma 81
4.5.8 Tisagenlecleucel-T -
Novartis 83
4.5.9 Conclusion 84
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1245341
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment